TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11202490

Group type: EXPERIMENTAL
Intervention: Repeated-exposure condition (five repetitions of 5 stimuli)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-exposure condition (5-ms exposures of 25 stimuli each shown once)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Repeated-exposure condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previously exposed stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New but similar stimuli
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stimuli from a different category
Number of subjects: 0
Study: 9364418

Group type: EXPERIMENTAL
Intervention: 50 mg codeine
Number of subjects: 82

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both codeine and placebo
Number of subjects: 82
Study: 1556249

Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Meridol I
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Meridol II
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Meridol
Number of subjects: 49
Study: 4011068

Group type: EXPERIMENTAL
Intervention: Digitally inserted rayon and cotton tampons (regular, super, super-plus)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Rayon polyacrylate tampon
Number of subjects: 100

Group type: COMPARATOR
Intervention: External sanitary protection
Number of subjects: 100
Study: 31969269

Group type: EXPERIMENTAL
Intervention: Cariprazine (modal dose <1.5, 1.5, 3 mg/d)
Number of subjects: 1775

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1775

Group type: EXPERIMENTAL
Intervention: Cariprazine (modal dose)
Number of subjects: 1775

Group type: EXPERIMENTAL
Intervention: Cariprazine (fixed dose 1.5 mg/d)
Number of subjects: 1775
Study: 31174162

Group type: EXPERIMENTAL
Intervention: Cumulative adversity score
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Adversity quintile
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Socioeconomic adversity
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Family-child relationship adversity
Number of subjects: 712

Group type: EXPERIMENTAL
Intervention: Child adversity
Number of subjects: 712

Group type: COMPARATOR
Intervention: Saliva cortisol measures
Number of subjects: 712
Study: 28440810

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amphetamine
Number of subjects: 0
Study: 25693969

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at four acupoints on the Stomach Meridian
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture at four acupoints on the Gallbladder Meridian
Number of subjects: 20
Study: 23527977

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NV)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Invasive ventilation (IV)
Number of subjects: 63
Study: 21310831

Group type: EXPERIMENTAL
Intervention: Intraduodenal oleic acid (18:1 load: 0.78 kcal/min)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Recent dietary intake
Number of subjects: 19
Study: 19738111

Group type: EXPERIMENTAL
Intervention: Stanford V
Number of subjects: 520

Group type: COMPARATOR
Intervention: ABVD
Number of subjects: 520
Study: 18626140

Group type: COMPARATOR
Intervention: Chlorpheniramine (12 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chlorpheniramine plus ephedrine (Chlorphedra: 12 mg C + 50 mg ephedrine)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Chlorpheniramine plus ephedrine (Chlorphedra)
Number of subjects: 18
Study: 14747117

Group type: EXPERIMENTAL
Intervention: Amiodarone prophylaxis in group 1B (n=100)
Number of subjects: 300

Group type: COMPARATOR
Intervention: No prophylaxis in group 1A (n=100)
Number of subjects: 300
Study: 11426104

Group type: EXPERIMENTAL
Intervention: Controlled hypercapnia
Number of subjects: 57

Group type: COMPARATOR
Intervention: Intermittent boluses of saline injected intrathecally (Control)
Number of subjects: 57
Study: 9261702

Group type: EXPERIMENTAL
Intervention: Cefazolin (for TBSA < 35%)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (for TBSA < 35%)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Cefazolin (for TBSA ≥ 35%)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Targeted antibiotics (for TBSA ≥ 35%)
Number of subjects: 23
Study: 8418349

Group type: EXPERIMENTAL
Intervention: Cyclosporine withdrawal
Number of subjects: 30
Study: 3536400

Group type: EXPERIMENTAL
Intervention: 1 g sucralfate suspension four times daily
Number of subjects: 134

Group type: COMPARATOR
Intervention: 150 mg ranitidine tablet twice daily
Number of subjects: 134

Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: sucralfate
Number of subjects: 134
Study: 2656368

Group type: EXPERIMENTAL
Intervention: 100 micrograms arbaprostil
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 50 micrograms arbaprostil
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 31133906

Group type: EXPERIMENTAL
Intervention: Digital health tools for early psychosis
Number of subjects: 48
Study: 29354917

Group type: EXPERIMENTAL
Intervention: Rehabilitation training combined with modified shu‐acupuncture for 8 weeks, acupuncture at specified points once a day for 6 days with 1 day rest.
Number of subjects: 71

Group type: COMPARATOR
Intervention: Simple rehabilitation training for 8 weeks, including quadriceps femoris exercises, range of knee joint motion, and limb walking on the affected side.
Number of subjects: 71
Study: 26165981

Group type: EXPERIMENTAL
Intervention: Guided Imagery (GI) intervention
Number of subjects: 36
Study: 23275644

Group type: EXPERIMENTAL
Intervention: Laparoscopy-assisted distal gastrectomy
Number of subjects: 920

Group type: COMPARATOR
Intervention: Open distal gastrectomy
Number of subjects: 920
Study: 21185506

Group type: EXPERIMENTAL
Intervention: Left ventricular (LV) dysfunction at diagnosis
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Mitral regurgitation (MR) at diagnosis
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Aortic root dilation at diagnosis
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Laboratory inflammatory markers (erythrocyte sedimentation rate and serum albumin)
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Aortic root size
Number of subjects: 198
Study: 18338263

Group type: EXPERIMENTAL
Intervention: Neostigmine 2 mg and glycopyrrolate 0.4 mg intramuscularly
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 7
Study: 16931684

Group type: EXPERIMENTAL
Intervention: Preincisional paravertebral block (PVB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no PVB)
Number of subjects: 60
Study: 12607809

Group type: EXPERIMENTAL
Intervention: Self-reported patient pain measured using the Visual Analog Scale and the Medical Outcomes Study Short Form‐36 (MOS SF‐36) pain scale.
Number of subjects: 509
Study: 11180026

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 800 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8938010

Group type: EXPERIMENTAL
Intervention: Haptic bias instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual bias instructions
Number of subjects: 0
Study: 1403999

Group type: EXPERIMENTAL
Intervention: Couple therapy (five sessions)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (no couple therapy)
Number of subjects: 56
Study: 2988737

Group type: EXPERIMENTAL
Intervention: Radiation therapy twice a week (40.00 Gy/5 weeks) with misonidazole 1.2 g/m2 given orally 3 1/2 to 4 hours before treatment
Number of subjects: 244

Group type: COMPARATOR
Intervention: Radiation therapy twice a week (40.00 Gy/5 weeks) with placebo
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Radiation therapy five times a week (50.00 Gy/5 weeks) with misonidazole 0.48 g/m2 given orally 3 1/2 to 4 hours before treatment
Number of subjects: 244

Group type: COMPARATOR
Intervention: Radiation therapy five times a week (50.00 Gy/5 weeks) with placebo
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: CCNU chemotherapy (120 mg/m2 every 6 weeks)
Number of subjects: 244

Group type: COMPARATOR
Intervention: No chemotherapy
Number of subjects: 244
Study: 29404913

Group type: EXPERIMENTAL
Intervention: Technique feature analysis
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Involvement load hypothesis
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sentence making, composition, and reading comprehension tasks
Number of subjects: 90
Study: 27600013

Group type: COMPARATOR
Intervention: General anesthesia and patient-controlled intravenous analgesia (PCIA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: General anesthesia combined with epidural anesthesia and PCIA
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: General anesthesia combined with epidural anesthesia and patient-controlled epidural analgesia (PCEA)
Number of subjects: 100
Study: 25037674

Group type: EXPERIMENTAL
Intervention: TAVR in patients with BAV
Number of subjects: 28

Group type: COMPARATOR
Intervention: TAVR in patients with tricuspid aortic valves (control group)
Number of subjects: 28
Study: 22396403

Group type: EXPERIMENTAL
Intervention: Perturbation of the arm at random times during decision formation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous flow of an evolving decision variable to the motor system
Number of subjects: 0
Study: 20675951

Group type: EXPERIMENTAL
Intervention: Culturally targeted educational program on colorectal health (90 minutes)
Number of subjects: 539

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 539
Study: 19255992

Group type: EXPERIMENTAL
Intervention: Sublingual midazolam (0.3 mg/kg)
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Oral chloral hydrate (50 mg/kg)
Number of subjects: 264
Study: 16186281

Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 21

Group type: COMPARATOR
Intervention: Human regular insulin
Number of subjects: 21
Study: 11505405

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, doxorubicin, and vincristine (CAV)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Single-agent carboplatin
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: CAV
Number of subjects: 119

Group type: COMPARATOR
Intervention: Carboplatin
Number of subjects: 119
Study: 9877257

Group type: EXPERIMENTAL
Intervention: Parents as the agents of change (experimental intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Children as the agents of change (conventional intervention)
Number of subjects: 60
Study: 8078438

Group type: EXPERIMENTAL
Intervention: Cyclic parenteral nutrition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cyclic total parenteral nutrition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous nutrient infusion
Number of subjects: 0
Study: 2510312

Group type: EXPERIMENTAL
Intervention: Mupirocin
Number of subjects: 111

Group type: COMPARATOR
Intervention: Tetracycline
Number of subjects: 111
Study: 1097619

Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP) early (0.40 FIO2; PaO2 < 60 mm Hg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuous Positive Airway Pressure (CPAP) late (0.70 FIO2; PaO2 < 60 mm Hg)
Number of subjects: 0
Study: 30629770

Group type: EXPERIMENTAL
Intervention: HP
Number of subjects: 388

Group type: COMPARATOR
Intervention: G + T
Number of subjects: 388
Study: 27501360

Group type: EXPERIMENTAL
Intervention: Speed-based exercise program (stationary recumbent cycling, 2 sessions per week, 30 minutes each, including interval training with ten 20-second fast cadence intervals)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Speed-based exercise program
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 26
Study: 26586255

Group type: EXPERIMENTAL
Intervention: Trained using the Gadjah Mada nurse-client communication guideline (4 hours of training with role-plays, supportive information, and feedback sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untrained students)
Number of subjects: 0
Study: 24392462

Group type: COMPARATOR
Intervention: Conservative treatment (72 patients)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Microsurgical discectomy (55 patients)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Both groups (Conservative and Operative)
Number of subjects: 127
Study: 22344061

Group type: EXPERIMENTAL
Intervention: Weightlifting
Number of subjects: 30

Group type: COMPARATOR
Intervention: Kettlebell training
Number of subjects: 30
Study: 19887581

Group type: EXPERIMENTAL
Intervention: Higher serum total cholesterol concentration (high versus low quintile, >276.7 versus <203.9 mg/dL)
Number of subjects: 29093

Group type: EXPERIMENTAL
Intervention: Greater HDL cholesterol (high versus low quintile, >55.3 versus <36.2 mg/dL)
Number of subjects: 29093
Study: 17699531

Group type: EXPERIMENTAL
Intervention: Walking programme (30 minutes brisk walking three days a week, n = 44)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Walking programme (30 minutes brisk walking five days a week, n = 42)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Control group (n = 20)
Number of subjects: 106
Study: 14987626

Group type: EXPERIMENTAL
Intervention: Deep muscle stimulation
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Subcutaneous needle insertion
Number of subjects: 15
Study: 11669568

Group type: EXPERIMENTAL
Intervention: Risk assessment, pressure ulcer grading, pressure-reducing mattress, and educational programme
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Nursing and treatment routines
Number of subjects: 146
Study: 9853541

Group type: COMPARATOR
Intervention: Wheat bran supplement (high-fiber control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Resistant starches (RS2 and RS3)
Number of subjects: 24
Study: 7865392

Group type: EXPERIMENTAL
Intervention: Elastic legging
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inelastic legging
Number of subjects: 0

Group type: COMPARATOR
Intervention: No legging (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elastic legging and Inelastic legging
Number of subjects: 0
Study: 2678390

Group type: EXPERIMENTAL
Intervention: Hemosorption
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo-hemosorption
Number of subjects: 9
Study: 1095283

Group type: EXPERIMENTAL
Intervention: Fenmetozole (100 mg and 200 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 30604197

Group type: EXPERIMENTAL
Intervention: Mannuronic acid (500 mg, two capsules per day orally for 12 weeks)
Number of subjects: 288

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Mannuronic acid
Number of subjects: 288
Study: 29231473

Group type: EXPERIMENTAL
Intervention: Combined therapy group (acupuncture + modified weitong xiaopi formula)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine group (modified weitong xiaopi formula)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Western medication group (mosapride citrate capsules)
Number of subjects: 90
Study: 25822117

Group type: EXPERIMENTAL
Intervention: Implementation intentions using standard instructions
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Implementation intentions with a supporting tool
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 79
Study: 23739503

Group type: EXPERIMENTAL
Intervention: 1000 mg of L-carnitine per day
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2000 mg of L-carnitine per day
Number of subjects: 60

Group type: COMPARATOR
Intervention: Basic therapy only (control group)
Number of subjects: 60
Study: 21384388

Group type: EXPERIMENTAL
Intervention: 2,940 nm Er:YAG laser device at adjustable depths (250 µm, 500 µm, 1,000 µm) and four coagulation levels
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: 2,940 nm Er:YAG laser device
Number of subjects: 3
Study: 19398668

Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 476

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 476
Study: 17416110

Group type: EXPERIMENTAL
Intervention: Ketamine (n=20): bolus dose of 0.5 mg x kg(‐1) followed by continuous infusion of 2 microg x kg(‐1) x min(‐1) before surgery.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n=20): normal saline in the same manner as ketamine group.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ketamine (n=20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (n=20)
Number of subjects: 40
Study: 15361700

Group type: COMPARATOR
Intervention: Serum oxLDL/beta2GPI complexes in patients with chronic renal failure (CRF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Serum oxLDL/beta2GPI complexes in patients with chronic nephritis (CN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Malondialdehyde-modified LDL in all patient groups
Number of subjects: 0
Study: 11195257

Group type: EXPERIMENTAL
Intervention: Moclobemide 600 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 9301431

Group type: EXPERIMENTAL
Intervention: Intravenous L-arginine 8 g
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intravenous L-arginine 30 g
Number of subjects: 20
Study: 2167573

Group type: EXPERIMENTAL
Intervention: Miansan (mianserin)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Pyrazidol
Number of subjects: 42
Study: 7019033

Group type: EXPERIMENTAL
Intervention: lysozyme chloride at doses of 60 to 170 mg/day for 4 to 24 weeks
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 260
Study: 30794114

Group type: EXPERIMENTAL
Intervention: Positive feedback
Number of subjects: 35

Group type: COMPARATOR
Intervention: Negative feedback
Number of subjects: 35

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 35
Study: 29020601

Group type: EXPERIMENTAL
Intervention: Pioglitazone (45mg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo (0mg)
Number of subjects: 27
Study: 26438225

Group type: EXPERIMENTAL
Intervention: Video-tailored intervention (personalised videos)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Text-tailored intervention (personalised text advice)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Control group (generic physical activity articles)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Video-tailored intervention
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Text-tailored intervention
Number of subjects: 510

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 510
Study: 23584570

Group type: EXPERIMENTAL
Intervention: FOYC intervention (delivered in 2004/2005)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (no training)
Number of subjects: 0
Study: 22648100

Group type: COMPARATOR
Intervention: High-fidelity simulator (LapSim)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Low-fidelity simulator (FLS)
Number of subjects: 228
Study: 20455246

Group type: EXPERIMENTAL
Intervention: Pexacerfont 100 mg/day
Number of subjects: 260

Group type: COMPARATOR
Intervention: Escitalopram 20 mg/day
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 260
Study: 18606032

Group type: EXPERIMENTAL
Intervention: Video‐Feedback Intervention to Promote Positive Parenting and Sensitive Discipline (VIPP‐SD)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 130
Study: 15739655

Group type: EXPERIMENTAL
Intervention: Information leaflet along with verbal information
Number of subjects: 20

Group type: COMPARATOR
Intervention: Verbal information alone
Number of subjects: 20
Study: 11918753

Group type: EXPERIMENTAL
Intervention: Combination therapy (enalapril 10 mg/day and eprosartan 300 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Enalapril (20 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Eprosartan (600 mg/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: All treatments
Number of subjects: 20
Study: 10512404

Group type: COMPARATOR
Intervention: Suction biopsy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Grasp biopsy
Number of subjects: 29
Study: 8973851

Group type: EXPERIMENTAL
Intervention: epirubicin 75 mg/m2
Number of subjects: 40

Group type: COMPARATOR
Intervention: mitozantrone 14 mg/m2
Number of subjects: 40
Study: 1333098

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens at 0.625 mg per day
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Conjugated estrogens at 1.25 mg per day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 3909910

Group type: EXPERIMENTAL
Intervention: 3 days of postoperative catheterisation
Number of subjects: 0

Group type: COMPARATOR
Intervention: 28 days of postoperative catheterisation
Number of subjects: 0
Study: 31305214

Group type: EXPERIMENTAL
Intervention: Metformin therapy for 3 months
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: CVAI
Number of subjects: 537

Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-euglycemic clamp
Number of subjects: 537
Study: 28581645

Group type: EXPERIMENTAL
Intervention: Nutritional protein-rich drink
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard breakfast
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fasted conditions
Number of subjects: 12
Study: 27690762

Group type: EXPERIMENTAL
Intervention: AS03-adjuvanted trivalent inactivated influenza vaccine (AS03-TIV)
Number of subjects: 5187

Group type: COMPARATOR
Intervention: Non-adjuvanted trivalent inactivated influenza vaccine (TIV)
Number of subjects: 5187

Group type: EXPERIMENTAL
Intervention: AS03-TIV
Number of subjects: 5187

Group type: COMPARATOR
Intervention: TIV
Number of subjects: 5187

Group type: EXPERIMENTAL
Intervention: Statistical model based on A/H3N2 attack rates and HI antibody titers
Number of subjects: 5187
Study: 25100080

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg once daily
Number of subjects: 452

Group type: EXPERIMENTAL
Intervention: Rabeprazole 5 mg once daily
Number of subjects: 452

Group type: COMPARATOR
Intervention: Teprenone 50 mg three times per day (active control)
Number of subjects: 452